FDA Approves Ceftazidime 1g and 2g for Use in B.Braun Medical's DUPLEX® System
Published: Jun 14, 2011
BETHLEHEM, Pa.June 13, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved B. Braun Medical Inc.'s (B. Braun) application for 1g and 2g Ceftazidime for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System.
The availability of 1g and 2g Ceftazidime in the DUPLEX® System will mean faster, safer and accurate administration of Ceftazidime to patients as it can be stored and ready-to-use wherever and whenever it is needed.
"B. Braun is adding 1g and 2g Ceftazidime within the DUPLEX® System to continue to meet customer demands for providing a broad spectrum of intravenous therapies," said Rob Albert, Vice President of Marketing for Pharmaceuticals & Drug Delivery for B. Braun Medical Inc. "The DUPLEX® System ensures sterility and accuracy through a ready-to-use, closed-system design with barcodes which ultimately contribute to reducing medication errors."
The DUPLEX® Drug Delivery System is a ready-to-use two-compartment, flexible, eco-friendly IV container that stores pre-measured drug and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature and fits in automated medication dispensing systems. DUPLEX® helps healthcare facilities achieve Surgical Care Improvement Project (SCIP), the Joint Commission and USP 797 compliance that improve the practice of healthcare professionals while advancing patient safety.
Healthcare workers administering 1g or 2g Ceftazidime through DUPLEX® simply fold and squeeze the container and shake it to mix the drug and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.
Customers interested in obtaining more information can call: 1-888-422-7286 (1-888-4BBRAUN).
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at email@example.com or visit B. Braun at www.bbraunusa.com.
SOURCE B. Braun Medical Inc.